VSTM: Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

New alert via PocketInfo for VSTM:

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Press Releases: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-news&nyo=0
SEC Filings: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8